Evidence map›Paper›PMID 40103593›Full record

ArticleFrontiers in pharmacology2025

Post-marketing safety re-evaluation of placental peptide injection in China: a large-scale multicenter real-world study.

Liguang Duan, Feiyue An, Chen Tian, Wen Yan, Jie Chen, Hongyin Zhang, Xiaoguang Liu, Lingjiao Wang, Zhuo Zhang, Binliang Tong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liguang Duan *Pharmacy Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Feiyue An *Pharmacy Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Chen TianPharmacy Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Wen YanPharmacy Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Jie ChenPharmaceutical Department, Kunming Third People's Hospital, Kunming, China.
Hongyin ZhangPharmacy Department, Yunnan Cancer Hospital, Kunming, China.
Xiaoguang LiuBeijing Dehuijia Pharmaceutical Technology Co., Ltd., Beijing, China.
Lingjiao WangDepartment of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Zhuo ZhangPharmacy Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Binliang TongPharmacy Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Chunhua ZhouDepartment of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study conducted a post-marketing safety re-evaluation of placental polypeptide injections in China to support updates to drug guidelines, pharmacovigilance efforts, and rational clinical use, facilitating its inclusion in essential drug lists and medical insurance coverage. Methods: A hospital-based centralized monitoring system tracked 3,000 patients receiving placental polypeptide injections across three medical institutions. Adverse drug reactions (ADRs) and adverse drug events (AEs) were systematically collected and analyzed. Results: The mean patient age was 49.65 years, with 96.47% being over 18 years of age. A single dose exceeding 4 mL was administered in 98.34% of the cases, with a median treatment duration of 7 days. Concomitant medication use was high (injectable, 98.43%; non-injectable, 75.43%). One case of vertigo was reported as an ADR in a patient aged >60 years who had melanoma. Conclusion: The ADR rate was 0.03%, confirming the favorable safety profile of placental polypeptide injection. These findings support its safe clinical use and can inform future regulatory and policy decisions.

Indexed as

adverse drug reactionscentralized hospital monitoring methodplacental peptide injectionpost-marketing safety re-evaluationreal-world study

Identifiers

PMID40103593
PMCPMC11913665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.